Norge - norsk - Statens legemiddelverk

2care4 aps - tiotropiumbromid - inhalasjonspulver, hard kapsel - 18 mikrog

Den europeiske union - norsk - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. hos voksne pasienter, for å kunne skille mellom sannsynlig demens med lewy legemer fra alzheimers sykdom.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Norge - norsk - Statens legemiddelverk

glenmark pharmaceuticals nordic ab - tiotropiumbromid - inhalasjonspulver, hard kapsel - 18 mikrog

Den europeiske union - norsk - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - immune sera og immunglobuliner, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Norge - norsk - Statens legemiddelverk

orifarm as - obetikolsyre - tablett, filmdrasjert - 5 mg

Norge - norsk - Statens legemiddelverk

orifarm as - obetikolsyre - tablett, filmdrasjert - 10 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Norge - norsk - Statens legemiddelverk

orifarm as - lenvatinibmesilat - kapsel, hard - 4 mg

Norge - norsk - Statens legemiddelverk

poa pharma scandinavia ab - ciprofloksacinhydroklorid - Øredråper, oppløsning - 2 mg/ ml

Norge - norsk - Statens legemiddelverk

novartis norge as - ciprofloksacinhydroklorid - Øredråper, oppløsning - 3 mg/ ml